Precision Biosciences Inc (DTIL)

Nov 17, 2024

Trading (DTIL) With Integrated Risk Controls - Stock Traders Daily

Nov 17, 2024

Nov 15, 2024

Gene Editing Tools Market Size, Growth Opportunities, - openPR

Nov 15, 2024

Nov 15, 2024

Precision BioSciences Reports 99% HBV Gene Editing Success, Unveils Phase 1 Trial Design | DTIL Stock News - StockTitan

Nov 15, 2024

Nov 14, 2024

JANUS HENDERSON GROUP PLC's Strategic Acquisition in Precision B - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Precision BioSciences stock hits 52-week low at $7.94 By Investing.com - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Precision BioSciences stock hits 52-week low at $7.94 - Investing.com

Nov 14, 2024

Nov 14, 2024

Highbridge Capital Management's Strategic Acquisition of Precisi - GuruFocus.com

Nov 14, 2024

Nov 07, 2024

What is HC Wainwright's Forecast for DTIL FY2024 Earnings? - MarketBeat

Nov 07, 2024

Nov 06, 2024

Research Analysts Offer Predictions for DTIL FY2027 Earnings - MarketBeat

Nov 06, 2024

Nov 06, 2024

(DTIL) Technical Data - Stock Traders Daily

Nov 06, 2024

Nov 05, 2024

Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 - Investing.com India

Nov 05, 2024

Nov 05, 2024

Precision Biosciences' general counsel sells $4,815 in stock - Investing.com

Nov 05, 2024

Nov 05, 2024

Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 By Investing.com - Investing.com UK

Nov 05, 2024

Nov 05, 2024

Precision BioSciences keeps $34 target, Market Perform rating By Investing.com - Investing.com Australia

Nov 05, 2024

Nov 04, 2024

Precision BioSciences: Q3 Earnings Snapshot - Darien Times

Nov 04, 2024

Nov 04, 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace

Nov 04, 2024

Nov 04, 2024

Precision BioSciences keeps $34 target, Market Perform rating - Investing.com

Nov 04, 2024

Nov 04, 2024

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 04, 2024

Nov 01, 2024

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN

Nov 01, 2024

Oct 31, 2024

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com

Oct 31, 2024

Oct 30, 2024

Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat

Oct 30, 2024

Oct 29, 2024

Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace

Oct 29, 2024

Oct 28, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Business Wire

Oct 28, 2024

Oct 26, 2024

(DTIL) Trading Report - Stock Traders Daily

Oct 26, 2024

Oct 26, 2024

Precision BioSciences stock hits 52-week low at $8.22 By Investing.com - Investing.com Canada

Oct 26, 2024

Oct 25, 2024

500: Something went wrong - Investing.com

Oct 25, 2024

Oct 25, 2024

Precision BioSciences stock hits 52-week low at $8.22 - Investing.com India

Oct 25, 2024

Oct 24, 2024

Precision BioSciences begins clinical trial for hepatitis B cure By Investing.com - Investing.com Australia

Oct 24, 2024

Oct 24, 2024

Precision BioSciences touts gene editing efficiency with ARCUS - Investing.com India

Oct 24, 2024

Oct 24, 2024

Precision BioSciences touts gene editing efficiency with ARCUS By Investing.com - Investing.com Canada

Oct 24, 2024

Oct 24, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Business Wire

Oct 24, 2024

Oct 24, 2024

Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance

Oct 24, 2024

Oct 24, 2024

Precision BioSciences, Inc. announced that it has received $25.65 million in funding from a group of investors. - Marketscreener.com

Oct 24, 2024

Oct 24, 2024

Precision BioSciences begins clinical trial for hepatitis B cure - Investing.com

Oct 24, 2024

Oct 24, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire

Oct 24, 2024

Oct 21, 2024

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - BioSpace

Oct 21, 2024

Oct 17, 2024

Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Drops By 7.1% - MarketBeat

Oct 17, 2024

Oct 16, 2024

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress - BioSpace

Oct 16, 2024

Oct 15, 2024

How the (DTIL) price action is used to our Advantage - Stock Traders Daily

Oct 15, 2024

Oct 10, 2024

Gene Editing Tools Market Poised for Massive Growth (2024-2031) - openPR

Oct 10, 2024